BridgeMD
STOP-IMH
EU CTIS ID: 2024-517783-37-00
What this study is testing
To assess whether direct omission of aspirin after primary PCI with the continuation of ticagrelor monotherapy for 12 months versus 12 months ticagrelor plus aspirin is equally safe regarding the incidence of ischemic events in STEMI patients. Furthermore, the two treatment strategies will be compared regarding the incidence and extent of IMH in the first week after PCI
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Clinical and electrocardiographical diagnosis of STEMI
- Successful PCI (according to the treating physician) of the infarct-related vessel with a modern DES
You likely can't join if
- Known allergy or contraindication for aspirin, ticagrelor or prasugrel.
- PCI of stent thrombosis
- Suboptimal stent result as judged by the interventional cardiologist
- Life expectancy shorter than 13 months
- Contra-indications for MRI or unable to undergo MRI (only applicable for the CMR subgroup population)
- Previous PCI or MI less than 12 months ago
See the full eligibility criteria
- Clinical and electrocardiographical diagnosis of STEMI
- Successful PCI (according to the treating physician) of the infarct-related vessel with a modern DES
- Known allergy or contraindication for aspirin, ticagrelor or prasugrel.
- PCI of stent thrombosis
- Suboptimal stent result as judged by the interventional cardiologist
- Life expectancy shorter than 13 months
- Contra-indications for MRI or unable to undergo MRI (only applicable for the CMR subgroup population)
- Previous PCI or MI less than 12 months ago
- Previous cardiac surgery
- Participation in another clinical cardiology study or study concerning platelet aggregation/ thrombosis (unless the antithrombotic therapy prescribed in this other study will end due to clinical reasons (e.g. the STEMI))
- Pregnancy and breast feeding
- Concurrent use of oral anticoagulants (OAC)
- The periprocedural use of GPIIb/IIIa inhibitors
- Planned surgical intervention within 12 months of PCI
- Creatinine clearance <30 mL/min or dialysis
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.